The current prevalent R&D trends related to AIP therapy focus on increasing hepatic PBGD activity (Figure 2 and Figure 3) and restoring the physiological regulation of the heme synthesis pathway. This evidence concerns the gene HMBS and autoimmune pancreatitis.